Home Business Ignore the letter of concern and get the “one” board Jiu’an Medical denies the speculation | Stock Price | Jiu’an Medical | Beijing Business News_Sina

Ignore the letter of concern and get the “one” board Jiu’an Medical denies the speculation | Stock Price | Jiu’an Medical | Beijing Business News_Sina

by news dir


Original title: Ignoring the letter of concern and getting a “one” board Jiu’an Medical denies the hype

When the stock price soared, the bull stock Jiu’an Medical (002432) was targeted by regulators, but this did not stop the enthusiasm of Jiu’an Medical’s stock price to continue to rise. On November 24, Jiu’an Medical again won the “one” board, and its stock price also hit a new high during the year. So far, Jiu’an Medical has received 8 consecutive daily limits. With its soaring share price, whether there is a situation in which Jiu’an Medical uses the interactive platform to speculate the company’s share price is also the focus of market and regulatory attention. On November 24, Wu Tong, Secretary of the Board of Jiu’an Medical, exclusively responded to a reporter from Beijing Business Daily, saying that “there is no deliberately driving up the stock price or speculating on the stock price.”

Gain 8 consecutive daily limit

Jiu’an Medical is undoubtedly a recent bull stock, and its stock price closed again on November 24.

The trading quotation showed that on November 24, Jiu’an Medical opened its daily limit at the opening of the morning market. As of the close of the day, the stock price of Jiu’an Medical was firmly sealed on the daily limit. On November 24, Jiu’an Medical closed 14.6 yuan per share, the intraday stock price hit a new high during the year, the stock price rose 10.02% that day, and the latest total market value was 6.988 billion yuan.

According to Oriental Fortune, the total transaction value of Jiu’an Medical on November 24 was 41.51 million yuan. When the stock price rose sharply, Jiu’an Medical also encountered investors’ rush to raise money. As of the close of trading on November 24, Jiu’an Medical’s daily limit position has been sealed for more than 100,000 lots.

A reporter from Beijing Commercial Daily noticed that since November 8th, the share price of Jiu’an Medical has begun to rise. According to Oriental Wealth, during the period from November 8th to 24th, the stock price of Jiu’an Medical has increased by 143.33%, and from November 15th to 24th, Jiu’an Medical has achieved 8 consecutive daily limits.

From a long-term perspective, under the form of post-restoration, from January 4 to November 5, 2021, the stock price of Jiu’an Medical has fallen by 33.78%. In less than half a month, Jiu’an Medical’s stock price has achieved a counterattack.

On the news, Jiu’an Medical issued an announcement on November 8, stating that the company learned in the early morning of November 6, 2021 (Saturday), Beijing time, that it was authorized by the U.S. Food and Drug Administration (FDA) that the company’s US subsidiary iHealth Labs Inc. (hereinafter referred to as “iHealth America”)’s new coronavirus (SARS-CoV-2) antigen home self-test OTC kit (colloidal gold immunochromatography) obtained emergency use authorization (EUA), details of the authorization It has also been publicized on the FDA official website on the same day. After obtaining the EUA, the product can be sold in the United States and countries/regions that recognize the US EUA during the public health emergency in the United States.

According to Jiu’an Medical, the product can be operated by individuals who collect pre-nasal swab samples by themselves, and the results can be quickly obtained in 15 minutes, making the detection process more convenient, fast, and low-cost, and it is convenient for individuals and families to quickly and timely screen for new coronary pneumonia. Investigation to help prevent and control the epidemic.

“After the above-mentioned products of the company’s subsidiary iHealth USA have obtained the FDA’s EUA, demanders can purchase them without a prescription and sell them through U.S. e-commerce, pharmacies, supermarkets and other channels. It is expected that it may bring related sales revenue to the company in the future. This test The products have enriched the company’s product line through EUA, which is an important breakthrough for the company in the field of IVD, which improves the company’s core competitiveness and market expansion capabilities, and provides professional and reliable new coronavirus detection solutions for more regions and countries around the world.” Jiu’an Medical said so.

In the opinion of independent economist Wang Chikun, when stocks have experienced huge short-term gains, investors should be cautious when investing and beware of chasing high quilts. Investment and financing expert Xu Xiaoheng also said that when choosing stocks, investors should conduct detailed research to avoid blindly following trends.

Company: There is no deliberate price bidding

After the positive disclosure, Jiu’an Medical recently responded to investors’ questions on the interactive platform, saying that “market demand is on the rise” and “kits have been sold locally to both the C-end and B-end” “the official of the kits” The sales price of the website is US$6.99 (1 serving). “The kit product belongs to the product category of the US federal government.” “The kit has started mass production and is selling well in the local spot.” “The current monthly production capacity is 100 million servings. “The plan estimates that the production capacity will increase to 200 million copies per month by the beginning of 2022.”

Jiu’an Medical, whose stock price has soared, has also been targeted by the Shenzhen Stock Exchange. On the evening of November 23, the Shenzhen Stock Exchange issued a letter of concern to Jiu’an Medical.

The Shenzhen Stock Exchange requires Jiu’an Medical to combine the company’s emergency use authorization period, market demand, selling price, capacity and capacity expansion plans, production and sales, market share, competing products, profitability and other factors to indicate that the company is on the interactive platform. Whether the relevant reply on the kit product is prudent and objective, whether it is based on facts and is consistent with the actual situation, whether there are misleading statements or publicity, advertising, or exaggerated statements, and explain the reasons.

The Shenzhen Stock Exchange also required Jiu’an Medical to state whether the company’s statements on the interactive e-commerce platform related to the kit product belong to the major events or the progress of major events as required by the “Stock Listing Rules (2020 Revision)” and the basis for its judgment. If it is, It further explained the reasons and compliance of the aforementioned circumstances that were not disclosed in the Authorized Announcement and the Announcement on Abnormal Stock Trading Fluctuations.

In addition, Jiu’an Medical also needs to self-examine the company’s recent media interviews, surveys from institutions and investors, and answers to investor inquiries, etc., to explain whether there is any violation of the accuracy, timeliness, and fairness of information disclosure, and whether there is any use Huoyiyi platform caters to market hotspots and hype about company stock prices.

In response to this, Wu Tong said in an interview with a reporter from Beijing Business Daily, “All the information we disclose on Huoyiyi is information that has been publicized in the announcement or on the FDA website. Apart from this information, we have not disclosed any other information. There is no situation of deliberately driving up the stock price or speculating on the stock price.”

A reporter from Beijing Business Daily noted that behind the skyrocketing stock price, Jiu’an Medical’s performance is lacking. The data shows that the operating income of Jiu’an Medical in the first three quarters of this year was about 790 million yuan, a year-on-year decrease of 50.82%; the corresponding realized net profit was about 50.128 million yuan, a year-on-year decrease of 86.19%. Wu Tong told reporters that the decline in performance in the first three quarters of this year is expected. Wu Tong specifically mentioned that the main reason for the decline in performance in the first three quarters of this year compared with the same period last year is that under the 2020 epidemic, the company’s thermometer products are anti-epidemic products, and the sales results are very good. Therefore, the company’s overall performance in 2020 is also historical sales. The year with the highest income.

When asked whether the new crown antigen home self-test OTC kit product will improve the company’s performance in 2021, Wu Tong said, “Our kit sales started in the second week of November, and the product was merged into a listed company. The 2021 annual report contains the sales revenue for November and December this year, but the specific amount is still unknown.”Beijing Commercial Daily reporter Liu Fengru


.

Related Articles

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.